By Billy Candra 
This pivotal discovery, detailed in a study published today in Nature Communications, introduces a novel therapeutic strategy that could revolutionise the standard of care for individuals diagnosed with early-stage breast cancer linked to inherited BRCA1 and BRCA2 gene mutations. The trial demonstrated that administering chemotherapy followed by a precisely timed course of a targeted cancer drug, olaparib, prior to surgery, allowed every patient in the intervention arm to survive the critical three-year period following their operation. This outcome represents a substantial leap forward in the fight against these particularly challenging forms of cancer, which have historically presented significant treatment hurdles.
The Breakthrough: A New Treatment Paradigm
The core of this breakthrough lies in the innovative sequencing and timing of existing treatments. Traditionally, patients with BRCA-mutated breast cancers receive chemotherapy and sometimes immunotherapy to shrink the tumour before surgical removal. While effective to a degree, this standard approach still carries a considerable risk of relapse or death within the first three years post-surgery, a period widely recognised as critical for long-term prognosis. The Partner trial, however, diverged from this established protocol by integrating olaparib, a PARP inhibitor already available on the NHS, into the neoadjuvant (pre-surgical) treatment regimen and, crucially, by introducing a carefully timed "gap" between the chemotherapy and the targeted drug.
The trial’s findings are particularly striking when compared to the control group, which received chemotherapy alone. In the intervention arm, comprising 39 patients who received the innovative chemotherapy-olaparib sequence, only one patient experienced a relapse three years after surgery, with an astounding 100% survival rate. In stark contrast, the control arm, consisting of 45 patients treated with chemotherapy only, saw a survival rate of 88% over the same period, with nine patients relapsing and six ultimately succumbing to the disease. This considerable disparity underscores the potential transformative impact of the new approach.
Understanding BRCA-Mutated Cancers: A Persistent Challenge
Breast cancers associated with faulty copies of the BRCA1 and BRCA2 genes are notoriously aggressive and difficult to treat. These genes play a crucial role in DNA repair, and mutations compromise this function, leading to an increased risk of various cancers, most notably breast and ovarian cancers. It is estimated that approximately 5-10% of all breast cancers are hereditary, with BRCA1 and BRCA2 mutations accounting for a significant proportion of these cases. For women carrying a BRCA1 mutation, the lifetime risk of developing breast cancer can be as high as 72%, while for BRCA2 carriers, it is around 69%.
Public awareness of BRCA gene mutations surged following actress Angelina Jolie’s preventative double mastectomy in 2013, after she discovered she carried a BRCA1 mutation. Her decision brought a much-needed spotlight on the genetic predispositions to cancer and the proactive measures individuals can take. However, for those already diagnosed with BRCA-related breast cancer, the journey often involves aggressive tumours that are harder to manage and more prone to recurrence. The standard of care has evolved over time, embracing chemotherapy, hormone therapy, and more recently, immunotherapy, yet the search for more effective and less toxic treatments remains paramount. The Partner trial directly addresses this unmet clinical need for a population facing an inherently higher-risk cancer.
The Partner Trial: Design and Methodology
The Partner trial was a multi-centre study, meticulously designed and led by Addenbrooke’s Hospital, part of Cambridge University Hospitals (CUH) NHS Foundation Trust, and the University of Cambridge. It recruited patients from 23 NHS sites across the UK, reflecting a broad national effort to address this critical area of cancer research. The trial’s innovative design hinged on two key elements: the incorporation of olaparib before surgery and the precise timing of its administration relative to chemotherapy.
Olaparib, taken as oral tablets, is a targeted cancer drug known as a PARP (poly-ADP ribose polymerase) inhibitor. PARP enzymes are involved in DNA repair, and by inhibiting them, olaparib exploits the existing DNA repair deficiencies in BRCA-mutated cancer cells, leading to their death. This concept, known as "synthetic lethality," is a cornerstone of precision oncology. What set the Partner trial apart was the strategic scheduling of these drugs. Patients first received chemotherapy, which damages cancer cell DNA. Then, critically, a 48-hour "gap" was observed before olaparib treatment commenced. Researchers hypothesised that this brief pause would allow a patient’s healthy bone marrow cells to recover from the immediate effects of chemotherapy, while the already damaged tumour cells would remain susceptible to the targeted action of olaparib. This hypothesis appears to have been validated by the exceptional outcomes.
Professor Jean Abraham, a consultant at Addenbrooke’s and the trial lead, explained that the idea for the 48-hour gap arose from a "chance conversation" with Mark O’Connor, chief scientist in Early Oncology R&D at AstraZeneca, the developer of olaparib. This serendipitous discussion, rooted in a deep understanding of cellular biology and drug mechanisms, ultimately led to a trial design that has yielded unprecedented results.
Patient Perspective: A Story of Hope
Behind the impressive statistics are real people whose lives have been profoundly impacted. Jackie Van Bochoven, 59, from South Cambridgeshire, is one such patient. Diagnosed in February 2019 with a small but aggressive tumour, Jackie’s initial reaction was one of profound shock and worry. "When I had the diagnosis, I was completely shocked and numb," she recalled. "I thought about my children, and my mum and sister who were diagnosed with breast cancer. I was pretty worried." Her family history undoubtedly heightened her anxiety, a common experience for those facing an inherited cancer.
However, six years on, Jackie stands as a testament to the success of this new treatment. "Six years on, I’m well and cancer free. I’m back at work, enjoying life and spending time with my family," she shared. Her experience underscores not only the physical healing but also the profound psychological shift that comes with overcoming such a formidable disease. "When you’ve had cancer, I think you look at life differently and every day is a bonus." Her story provides a powerful human dimension to the scientific achievement, highlighting the potential for patients to reclaim their lives and futures.
Olaparib: A Targeted Therapy’s Evolution
Olaparib (marketed as Lynparza) represents a significant advancement in targeted cancer therapy. It was initially approved in 2014 for treating advanced ovarian cancer in patients with BRCA mutations, marking a pivotal moment in the era of precision medicine. Its applications have since expanded to include certain types of prostate and pancreatic cancers, and notably, it is also approved for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer post-surgery.
The innovation in the Partner trial lies in shifting olaparib’s role to the neoadjuvant setting, prior to surgery, and in combining it with chemotherapy in a specific timed sequence. This pre-surgical application offers several potential advantages: it can shrink the tumour, potentially allowing for less extensive surgery; it provides an early indication of treatment response; and it targets residual cancer cells more effectively before they have a chance to spread. Furthermore, the trial demonstrated that a shorter course of olaparib – 12 weeks pre-surgery compared to the standard 12 months post-surgery for some indications – could achieve superior results, with significant implications for patient burden and healthcare costs.
Expert Voices: Reactions and Endorsements
The scientific and medical communities have reacted to these findings with considerable excitement and cautious optimism. Professor Jean Abraham articulated the significance, stating, "It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer. We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers." Her emphasis on the rarity of such a high survival rate in aggressive cancers highlights the magnitude of this achievement.
Mark O’Connor, whose "chance conversation" sparked the critical 48-hour gap hypothesis, added, "The Partner trial highlights the importance of detecting and treating cancer early, and the value of innovative science in informing clinical trial design, in this case using bone marrow stem cells to identify the combination gap schedule." He stressed the need for validation in larger studies but acknowledged the "incredibly exciting" potential to transform outcomes for patient populations with unmet clinical needs.
Michelle Mitchell, Chief Executive of Cancer Research UK, one of the trial’s funders, echoed this sentiment: "One of the best ways that we can beat cancer sooner is by making more effective use of treatments that are already available to us." She emphasised that while the research is "still in its infancy," it represents an "exciting discovery" that could give patients "more time with their loved ones." Mitchell also highlighted the broader goal of finding "safer and kinder ways to treat certain types of cancer" and stressed the necessity of further, larger studies before NHS implementation.
Broader Implications: Beyond Breast Cancer
The impact of the Partner trial extends beyond early-stage BRCA-mutated breast cancer. The findings have the potential to be applied to other cancers caused by faulty copies of BRCA genes, such as some ovarian, prostate, and pancreatic cancers, where PARP inhibitors are already used or being investigated. This could pave the way for more effective treatment strategies across a spectrum of hereditary cancers, leveraging the principles of precision medicine.
Moreover, the trial’s economic implications are substantial. The current standard for some olaparib indications involves a 12-month course of the drug post-surgery. The Partner trial demonstrated superior outcomes with just 12 weeks of pre-surgical olaparib. This significant reduction in treatment duration could lead to substantial cost savings for healthcare systems like the NHS, making advanced therapies more sustainable and accessible. Reduced treatment duration also translates to a lower burden on patients, potentially fewer side effects, and an improved quality of life during treatment.
The Road Ahead: Validation and Implementation
While the results of the Partner trial are exceptionally promising, the researchers acknowledge that further validation is crucial. Professor Abraham and her team are already planning the next phase of research: a larger, multicentre study designed to replicate these results in a broader patient population. This larger study will also aim to confirm that the Partner approach offers a less toxic treatment regimen for patients, in addition to being more cost-effective compared to current standard care. Such a comprehensive evaluation is essential before widespread adoption within national healthcare systems.
The journey from groundbreaking trial results to routine clinical practice is often lengthy, involving further trials (typically Phase III studies), regulatory approvals, and health technology assessments. However, the strength of the Partner trial’s early results provides a powerful impetus for accelerated development. The potential for a 100% survival rate in a high-risk patient group is a compelling argument for prioritising this research.
A Model of Collaboration: Cambridge’s Vision
The success of the Partner trial is a powerful testament to the value of collaborative research. It exemplifies the vision underpinning the Cambridge Cancer Research Hospital, a specialist facility currently slated for construction on the Cambridge Biomedical Campus, Europe’s leading life sciences hub. This hospital aims to integrate clinical expertise from Addenbrooke’s Hospital with world-class scientific research from the University of Cambridge, the Cancer Research UK Cambridge Centre, and industry partners. The goal is to create a synergy that drives the development of new diagnostics and treatments, enabling earlier cancer detection and the delivery of truly personalised, precision medicine.
This collaborative model, where academic insights meet industrial innovation and clinical application, is increasingly recognised as the most effective way to accelerate medical breakthroughs. The "chance conversation" that led to the 48-hour gap highlights how such cross-disciplinary dialogue can yield unexpected yet profound scientific advancements.
Funding and Support
The Partner trial was made possible through the generous support and sponsorship of several key organisations. It was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, reflecting the deep institutional commitment to advancing medical science. Funding was provided by Cancer Research UK, a leading charity dedicated to cancer research, and AstraZeneca, the pharmaceutical company behind olaparib. Further crucial support came from the NIHR Cambridge Biomedical Research Centre, the Cancer Research UK Cambridge Centre, and Addenbrooke’s Charitable Trust (ACT), underscoring the broad-based effort required to bring such transformative research to fruition.
In conclusion, the Partner trial represents a monumental stride forward in the treatment of aggressive, inherited breast cancers. By ingeniously combining existing therapies with precise timing, Cambridge researchers have demonstrated a path towards achieving unprecedented survival rates. While further research is needed to validate these findings on a larger scale, the initial results offer profound hope for patients and underscore the immense potential of precision medicine and collaborative scientific endeavour to redefine cancer care.
